대한뉴팜

Daehan New Pharm launched ‘DH Luthione Injection,’ a glutathione (GSH, glutathione sulfhydryl) drug recognized for its powerful antioxidant function, detoxification, and immune-enhancing effects. Glutathione is a small protein composed of three amino acids—cysteine, glutamic acid, and glycine—produced mainly in animal cells, especially in the liver. Its primary functions include antioxidation, detoxification, immune system enhancement, and anti-inflammatory effects. Other antioxidants such as vitamins C and E depend on glutathione, making it the most potent antioxidant known. In industrial animals, glutathione’s functions can prevent productivity loss caused by various stresses and frequent drug exposure, supporting its long-term use in livestock. However, most glutathione products approved for animals are oral formulations, which show low bioavailability due to poor absorption, limiting their effectiveness. Particularly during vaccinations such as foot-and-mouth disease, there was a need to develop injectable formulations that maximize stress relief, reduce inflammation, and boost immunity. To maximize effects, Daehan New Pharm used the same formulation and high-quality raw materials (from Kyowa Hakko Bio Co., Ltd.) as its leading human glutathione injection ‘Luthione Injection’ to develop ‘DH Luthione,’ the first freeze-dried glutathione injectable for animals. Clinical trials at Gyeongsang National University Veterinary College demonstrated that ‘DH Luthione’ effectively reduced stress and inflammation markers (cortisol, TNF-α, CRP) after foot-and-mouth disease vaccination. It significantly increased cell-mediated immunity (IFN-γ) and humoral immunity markers (IgG, IgM, IgA), and improved liver function markers (AST, ALT, bilirubin) while raising albumin levels. These verified benefits make ‘DH Luthione’ a valuable agent for enhancing productivity in industrial animals.

Daehan New Pharm launched ‘TASS-UP,’ a compressed cog thread product for the facial thread lifting market. In August 2018, the company signed an exclusive sales agreement with Gishell Group (CEO Kim Jong-woo) for the premium facial thread lift product ‘TESSLIFTSOFT.’ Following this, by releasing TASS-UP, which is the most popularly used compressed cog thread in the market, Daehan New Pharm has further strengthened its position in the facial thread lifting sector. Facial thread lifting, one of the most popular procedures for maintaining a youthful face, has recently gained popularity over methods like Botox, which have short durations, or fillers that may carry higher risks of side effects. TESSLIFT, launched last year, is known for its 3D mesh structure that provides natural lifting and volumizing effects, with a longer-lasting impact that has made it especially popular among young women. However, patients with sagging skin or deep nasolabial folds require stronger lifting effects. Industry experts emphasize that a combination treatment of compressed cog threads like TASS-UP is necessary for such cases. TASS-UP features thicker cogs than traditional sliced-cut threads, resulting in longer-lasting and more powerful lifting effects, making it suitable for a variety of patients. It is produced using a non-heating process, minimizing degradation of thread components due to heat, which addresses the common problem of thread breakage during long-term storage. Unlike bidirectional cogs, TASS-UP’s three-dimensional cogs are twisted at a consistent angle, enhancing lifting effectiveness. According to ISAPS (International Society of Aesthetic and Plastic Surgery), Korea’s face lifting market is expected to surge from approximately 10 billion won in 2016 to about 35 billion won by 2020. Thread lifting procedures are favored by clinicians due to their relative ease of performance and low incidence of side effects. Dr. Choi Ho-seong of Pionacl Clinic stated, “By using the newly released TASS-UP to achieve strong lifting effects and appropriately combining it with the natural, firm, and long-lasting TESSLIFTSOFT, patient satisfaction can be greatly increased.” Dr. Lee Sang-bong of Wonjin Dermatology Clinic noted, “TASS-UP and TESSLIFTSOFT not only produce synergistic effects but also complement the shortcomings of each thread, enhancing both efficacy and cost-effectiveness.” Daehan New Pharm is strengthening its position as a pharmaceutical bio company specializing in obesity and beauty products. Following a stable launch of facial thread lifting, the company plans to expand its portfolio of facial aesthetic products by introducing various medical devices.

Daehan New Pharm announced on the 14th that its cumulative operating profit for the third quarter increased approximately 44.5% year-on-year to 14.8 billion won. Sales declined about 9% to 90.2 billion won, while net profit turned positive. The significant improvement was driven by expanded sales of high-margin products and the establishment of an efficient management system. The company has been strengthening its product portfolio, improving distribution channels, and optimizing costs, creating a virtuous cycle by reinvesting profits into research and development to drive future growth. Operating efficiency enhancements contributed to performance improvements, with strategic new products such as ‘Same injection’ ‘Thymosin injection,’ and ‘TESSLIFTSOFT’ at the core of ongoing growth efforts. ‘Same injection,’ approved as a treatment for depression, is also known for its excellent effects in cancer adjunct therapy, liver function improvement, and pain management, and is expected to continue the reputation of ‘Luthione Injection’ (commonly known as ‘Baekok Injection’) as a sales leader. The company has an exclusive sales agreement for the premium mesh-structured dissolvable thread ‘TESSLIFTSOFT’ and is actively marketing its differentiated product strengths. Through diversification of sales and improvement of profitability structure, sales increased from 56.7 billion won in 2013 to 130.8 billion won last year, while operating profit rose from 6 billion won to 13.1 billion won.

In the first half of 2018, Daehan New Pharm recorded sales of 61.469 billion won, a decrease of approximately 5% compared to the same period last year. However, operating profit rose significantly by about 44% to 9.46 billion won from 6.563 billion won in the previous year. Due to increased other expenses, the company recorded a net loss of 3.881 billion won. Gradual improvements in financial structure and cost efficiency have steadily strengthened the company's fundamentals. The newly launched non-reimbursed injection ‘Same injection’ and the upcoming anticancer adjunct ‘Thymosin injection’ are expected to contribute to sales growth in the second half, supported by active seminars and both online and offline promotions.

Daehan New Pharm announced that its consolidated operating profit for the first half of 2018 reached 9.46 billion won, representing a 44% increase compared to the same period the previous year. Sales slightly decreased to 61.469 billion won, and net loss amounted to 3.881 billion won due to increased other expenses. The company has been strengthening its market position recently with the launch of the non-reimbursed injection ‘Same injection’ and plans to release the anticancer adjunct ‘Thymosin Injection.’ In July, Daehan New Pharm signed an exclusive sales contract for the next-generation premium dissolvable thread ‘TESSLIFTSOFT.’ Demand for the livestock stress reliever ‘Power GABA-C’ surged due to the record heatwave. Power GABA-C is user-friendly and proven effective against stress, dehydration, and reproductive disorders, with demand already exceeding production plans. Continuous efforts to improve financial structure and optimize costs are showing positive results. The new injection ‘Same injection’ and the upcoming anticancer adjunct ‘Thymosin Injection’ are expected to contribute to sales growth in the second half, supported by active seminars and online/offline promotions.

'DH Pulvisin Granules' was launched in June as a prevention and treatment for skin fungal infections caused by fungi such as Tinea, Trichophyton, and Microsporum, which are major skin diseases in companion animals (dogs and cats). Skin fungal infections in companion animals, known as ringworm, are highly contagious zoonotic diseases that can easily spread to owners and cohabiting pets if not properly treated. Various antifungal agents are used for treatment. The active ingredient in 'DH Pulvisin Granules', griseofulvin, is widely known to be highly effective against skin fungal infections. However, the use of human drugs without confirmed efficacy or safety in companion animals has been common. Clinical and toxicity trials of 'DH Pulvisin Granules' conducted at Seoul National University Veterinary College confirmed its excellent efficacy and safety in treating skin fungal infections in companion animals. It received approval in February 2018 as the only veterinary drug containing griseofulvin. This is not merely a substitute for human drugs but the only product scientifically and systematically verified in animals, offering significant assistance in treating skin fungal infections in companion animals.

Daehan New Pharm is solidifying its market position by consecutively launching non-reimbursed injections this year. Following the release of ‘Collapleo,’ a non-reimbursed injection containing atelocollagen in the first half, the company launched ‘Same injection', a non-reimbursed injection containing SAMe, on the 25th. An anticancer adjunct, ‘Thymosin Injection,’ is also scheduled for future release. ‘Same Injection' contains S-Adenosyl-L-Methionine (SAMe) as its main ingredient, which supports methylation within cells and activates homocysteine metabolism. Methylation is an epigenetic alteration affecting gene expression through chemical changes in the DNA sequence without altering the base sequence itself. Reduced methylation in cells can lead to various conditions: cancer, arteriosclerosis, and aging in adults; ADHD and autism in children; and neural tube defects in fetuses. Clinical studies have revealed that SAMe activates the TetraHydroBiopterin (BH4) cycle, which increases neurotransmitters serotonin and dopamine, improving depression, and provides strong antioxidant effects that alleviate pain from diseases such as alcoholic liver disease and arthritis. Many functional medicine and intravenous injection, experts expect ‘Same Injection', with SAMe to aid in the adjunct treatment and prevention of various diseases by acting on diverse and important metabolic mechanisms in the body. Director Ji Young-mi of the Korean Society of Intravenous Therapy (and head of the Seoul St. Mary’s Neurosurgery Functional Medicine Research Center) stated, ‘Same Injection' can provide significant help in the prevention and treatment of many intractable diseases increasing across various age groups in modern society.” ‘Same Injection' is gaining attention across diverse fields ranging from cosmetic surgery, anti-aging, wrinkle improvement, and fatigue relief to adjunctive care for cancer patients, expanding both its prescription scope and market size. According to the Korea Institute for Health and Social Affairs, the market size for non-reimbursed injections has grown rapidly every year since surpassing 1 trillion won. Alongside previously launched Iscador and Selen Injection, and upcoming Thymosin Injection, ‘Same Injection' is expected to form a key pillar in anticancer adjunctive therapy. Daehan New Pharm has ambitious plans to revamp the intravenous injection market by promoting ‘Same Injection' aggressively through online and offline channels in the second half of the year, aiming to grow it into a major pillar of their injection business.

DHNP’s research institute has registered a patent for a method to isolate and culture specific fibroblasts with superior skin regeneration effects from the heterogeneous fibroblast population, which is the main material for autologous fibroblast therapies. Existing research and products primarily isolate fibroblasts from the dermal tissue behind the patient’s ear and expand them for use in treating skin depressions, wrinkles, and refractory dermatitis. However, these therapies based on heterogeneous fibroblasts have shown lower efficacy compared to existing treatments and cosmetic fillers, leading to limited market acceptance. The research team stated, “Using this patented method, we successfully isolated papillary dermal fibroblasts, which exist in a specific dermal location, have superior proliferative ability, and play a central role in skin aging. Applying these fibroblasts in cell therapies is expected to yield significantly better effects compared to conventional fibroblast therapies.” The “High-purity Isolation Method for Papillary Dermal Fibroblasts” employs transwell technology to separate highly active papillary dermal fibroblasts from heterogeneous fibroblast populations with high purity. Cells isolated using this method demonstrated about seven times higher levels of skin regeneration factors characteristic of papillary dermal fibroblasts and exhibited excellent proliferative capacity. Furthermore, an increase in papillary dermal fibroblast factors was observed proportional to the number of culture passages, with stable maintenance and expansion confirmed. Thus, this differentiation and purification technology for specific fibroblasts establishes Daehan New Pharm’s foothold in the global cell therapy market, which is growing annually by 9.4% (expected to reach $344 billion in 2021 from $241 billion in 2017 according to Frost & Sullivan) and the domestic cell therapy market, expanding at an annual rate of 25%. Recently, DHNP relocated its bio research institute to Osong KBIO and is actively pursuing biopharmaceutical development. It has developed a high-efficiency cell culture system for fibroblast therapy and is applying serum-free media from its Japanese partner CSTI in cell therapy production.

Operating profit grew by 32% year-over-year in the first quarter. Operating profit reached 4.2 billion won, with ordinary profit at 2.2 billion won. Growth was driven by the establishment of a revenue-centered management system.